Challenges to medication adherence for morbidities during menopause
• The significant milestone of menopause is associated with the risk of weight gain, poor bone health, chronic diseases, and cancers1,6,9, 11, 12
• Medication adherence during menopause is poor. The primary barriers are enhanced menopause symptoms and multimorbidity fuelled by poor psychological health17, 20, 24.
Risk of morbidities during menopause
Menopause is a natural and among the first manifestation of the aging process in women marking an end of the fertility period. It is a multidimensional physiological transition as ovaries reduce their function resulting in receding levels of female sex hormones – estrogen and progesterone. The accompanying physical and psychological changes result in well-known physical discomforts. As women transit through this stage of life, they also become susceptible to other age-associated health concerns like unintended weight gain, poor bone health, chronic diseases, and cancers. This article describes these comorbidities and the challenges women face in adhering to their treatment during menopause.
Weight-gain: Unhealthy weight gain especially adipose deposition/redistribution in the central or visceral region is common in menopausal women, likely due to hormonal changes and increasing age, lower physical activity, and chronic health conditions1. According to an American survey on peri- and post-menopausal (40-59 year old) women 68% were found to be obese. The risk of obesity is higher in women undergoing unnatural menopause due to the removal of either ovaries or uterus or both as compared to premenopausal/early-perimenopausal women2. Importantly, obesity provides the basic framework for other chronic diseases to develop putting menopausal women at higher risk for diabetes and cardiovascular diseases3,4.
Urinogenital complications: Pelvic floor disorders, urinary incontinence, and incidence of urinary tract infections (UTI) increase in women undergoing menopause5. Lower estrogen levels result in an altered urobiome and disruption of the urothelial barrier is favorable for the growth of “bad” bacteria causing recurrent UTIs that require repeated antibiotic treatments. Similarly, declining estrogen levels may reduce the strength of pelvic floor muscles, contributing to the occurrence of urinary incontinence in menopausal women5.
Cardiovascular diseases (CVD): Studies point toward a higher risk of cardiovascular diseases post-menopause6. Increase in CVD could be due to changes in risk factors as women transition through menopause, due to both menopause and chronological aging-associated factors. Lower estradiol (E2) and higher follicle-stimulating hormone (FSH) during menopause are associated with atherosclerosis7. The relative CVD risk is higher in women experiencing an early onset of menopause (aged <45 years), either due to natural causes or surgical removal of ovaries6. If initiated at the right time, the estrogenic component from HRT exerts an early beneficial effect on healthy endothelium. It leads to a reduction in the risk of coronary heart disease (RR 0.52, 95% CI 0.29 to 0.96) and overall mortality (RR 0.70, 95% CI 0.52 to 0.95) when started in women between 50-60 years or within 10 years after the menopause onset8.
Type-2 diabetes mellitus (T2DM): Menopause as an independent risk factor of diabetes is a matter of contention. . Change in the hormonal landscape leads to a relative increase in androgenicity, insulin resistance, sleep disorders, mood fluctuations, and weight gain during menopause increases the risk of T2DM9,10 All these factors are associated with elevated blood glucose and insulin resistance10.
Poor Bone health: Females start losing bone density gradually from the age of 30 years. However, it nose-dives during menopause transition. The rapid loss of bone mass begins a year before the final menstrual period and continues to decline for the next two years, before plateauing; resulting in adverse changes in bone macrostructure and microarchitecture. The loss of bone density is also associated with reduced estrogen levels increasing osteoporosis and fracture risk in older women11.
Cancers: Unhealthy BMI in women approaching menopause is a high-risk factor for developing breast cancer. Women with higher BMI have 2-fold higher levels of estrogens and also higher levels of circulating estrogens which increases the risk of breast cancer12. The risk of ovarian cancer is also higher in post-menopausal women with a reproductive history of miscarriages, stillbirth, and higher age during the first gestation13. While the cancer risk is shown to be higher with the use of hormone replacement therapy (HRT) for menopause symptoms, users shall consider that not all treatments are the same and may impact differently the risk of endometrial and breast cancer14,15.
Medication adherence concerns for comorbidities during menopause
Medication adherence is of foremost importance to achieve the expected efficacy of a treatment therapy in the “real-world” clinical practice. Failure to adhere causes avoidable health complications and is a significant medical and financial burden16. For more information on the impact of menopause on women’s life, please refer to our article Menopause’s impact on women’s lives and adherence to treatment during the peri- and post-menopausal period.
Listed below are reasons for non-adherence to treatment for comorbidities during menopause:
• Menopausal symptoms: The complex physiological changes during menopause result in varied symptoms and form an important barrier to medication adherence (as discussed in a previous article in this series- Menopause’s impact on women’s lives and adherence to treatment during the peri- and post-menopausal period). A common reason for poor adherence to breast cancer treatment in menopause is the enhancement of menopausal symptoms due to the therapy-mediated lowering of sex hormones17. Similarly, women with HIV report challenges in adhering to retroviral therapy due to an increase in the severity of menopause symptoms18. Adherence to bisphosphonates prescribed for osteoporosis treatment in menopause is suboptimal due to enhanced side effects19.
• Multimorbidity: Menopausal women are likely to suffer from more than one health issue20. The adherence rate is known to be poor for multimorbidities employing complex drug regimens and is inversely proportional to the number of medications prescribed. Lifestyle changes are foremost for chronic diseases and are often not adhered to by middle-to-old aged patients.
• Socio-demographic factors: Older adults have enhanced difficulty in adhering to the prescribed therapy. A clinical trial reported failure in understanding the written health information in the majority of women participants resulting in non-adherence to their medications21. Low education level is also an important factor for false illness perceptions and causes difficulties in making appointments, accessing prescriptions, and requesting prescription refills as well. Studies have also highlighted gender-specific differences in medication adherence. Also, there exists a gender bias in medication development that could result in higher side effects experienced by female patients22. Older females are also more likely to face financial barriers in accessing healthcare and medications due to inadequate health insurance or dependence on other family members23. Additionally, a social support network is essential for treatment adherence. Menopausal women find themselves in want of social support as they deal with the death of elderly parents, empty-nest syndrome, and separation from a long-time partner due to divorce or death.
• Psychological issues: Lower sex hormones adversely influence mental health during menopause, elevating stress, anxiety, irritability, and depression24. Poor mental health clouds the rational-decision making process (See – Two systems of thinking: Why do rational people make irrational choices) and is associated with forgetfulness, an unhealthy lifestyle, and suboptimal treatment adherence.
• Healthcare-associated factors: Healthcare practitioners and other healthcare resources are important determinants of medication adherence (See- Healthcare practitioners: a potential springboard to success in medication adherence). Effective communication about drug regimens, dosage, and potential adverse effects is often lacking during healthcare visits21. The stigma associated with menopausal symptoms impedes effective communication between the provider and the patient.
Conclusion
The reasons for non-adherence to treatments during menopause are varied and complex, therefore the solutions should also be multifactorial. Medications that enhance the menopausal symptoms need to be carefully discussed and possibilities of alternative therapies should be explored to enhance adherence. Importantly, diagnosis and appropriate treatment of menopausal symptoms will help alleviate the non-adherence due to drug side effects in chronic diseases. Finally, compassionate communication with the HCP/pharmacists will help women struggling with the lack of social support and have the potential to enhance medication adherence21.
Sometimes you will be in control of your illness and other times you’ll sink into despair, and that’s OK! Freak out, forgive yourself, and try again tomorrow.” — Kelly Hemingway
References
1. Lovejoy JC, Champagne CM, de Jonge L, Xie H, Smith SR. Increased visceral fat and decreased energy expenditure during the menopausal transition. Int J Obes (Lond). Jun 2008;32(6):949-58. doi:10.1038/ijo.2008.25
2. Sutton-Tyrrell K, Zhao X, Santoro N, et al. Reproductive hormones and obesity: 9 years of observation from the Study of Women’s Health Across the Nation. Am J Epidemiol. Jun 1 2010;171(11):1203-13. doi:10.1093/aje/kwq049
3. Lee HR, Shin J, Han K, et al. Obesity and Risk of Diabetes Mellitus by Menopausal Status: A Nationwide Cohort Study. J Clin Med. Nov 6 2021;10(21)doi:10.3390/jcm10215189
4. Manrique-Acevedo C, Chinnakotla B, Padilla J, Martinez-Lemus LA, Gozal D. Obesity and cardiovascular disease in women. Int J Obes (Lond). Jun 2020;44(6):1210-1226. doi:10.1038/s41366-020-0548-0
5. Alperin M, Burnett L, Lukacz E, Brubaker L. The mysteries of menopause and urogynecologic health: clinical and scientific gaps. Menopause. Jan 2019;26(1):103-111. doi:10.1097/GME.0000000000001209
6. Matthews KA, Crawford SL, Chae CU, et al. Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition? J Am Coll Cardiol. Dec 15 2009;54(25):2366-73. doi:10.1016/j.jacc.2009.10.009
7. El Khoudary SR, Wildman RP, Matthews K, Thurston RC, Bromberger JT, Sutton-Tyrrell K. Endogenous sex hormones impact the progression of subclinical atherosclerosis in women during the menopausal transition. Atherosclerosis. Nov 2012;225(1):180-6. doi:10.1016/j.atherosclerosis.2012.07.025
8. Boardman HM, Hartley L, Eisinga A, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev. Mar 10 2015;(3):CD002229. doi:10.1002/14651858.CD002229.pub4
9. Slopien R, Wender-Ozegowska E, Rogowicz-Frontczak A, et al. Menopause and diabetes: EMAS clinical guide. Maturitas. Nov 2018;117:6-10. doi:10.1016/j.maturitas.2018.08.009
10. Kim C. Does menopause increase diabetes risk? Strategies for diabetes prevention in midlife women. Womens Health (Lond). Mar 2012;8(2):155-67. doi:10.2217/whe.11.95
11. Karlamangla AS, Burnett-Bowie SM, Crandall CJ. Bone Health During the Menopause Transition and Beyond. Obstet Gynecol Clin North Am. Dec 2018;45(4):695-708. doi:10.1016/j.ogc.2018.07.012
12. Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE. Adult weight change and risk of postmenopausal breast cancer. JAMA. Jul 12 2006;296(2):193-201. doi:10.1001/jama.296.2.193
13. Riman T, Nilsson S., Persson I. R. Review of epidemiological evidence for reproductive and hormonal factors in relation to the risk of epithelial ovarian malignancies.Acta Obstet Gynecol Scand. 2004: 83: 783–795
14. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases. BMJ. Oct 28 2020;371:m3873. doi:10.1136/bmj.m3873
15. Tempfer CB, Hilal Z, Kern P, Juhasz-Boess I, Rezniczek GA. Menopausal Hormone Therapy and Risk of Endometrial Cancer: A Systematic Review. Cancers (Basel). Aug 6 2020;12(8)doi:10.3390/cancers12082195
16. Bosworth HB. Enhancing Medication Adherence. Springer Healthcare Tarporley; 2012.
17. Moon Z, Moss-Morris R, Hunter MS, Hughes LD.Understanding tamoxifen adherence in women with breast cancer: A qualitative study.Br J Health Psychol. 2017 Nov;22(4):978-997. doi: 10.1111/bjhp.12266.
18. Vieria HP, Leite IA, et al. Bisphosphonates adherence for treatment of osteoporosis. Int Arch Med. 2013 May 24;6(1):24. doi: 10.1186/1755-7682-6-24.
19. Duff PK, Money DM, Ogilvie GS, et al. Severe menopausal symptoms associated with reduced adherence to antiretroviral therapy among perimenopausal and menopausal women living with HIV in Metro Vancouver. Menopause. May 2018;25(5):531-537. doi:10.1097/GME.0000000000001040
20. Xu X, Jones M, Mishra GD. Age at natural menopause and development of chronic conditions and multimorbidity: results from an Australian prospective cohort. Hum Reprod. Jan 1 2020;35(1):203-211. doi:10.1093/humrep/dez259
21. Jin H, Kim Y, Rhie SJ. Factors affecting medication adherence in elderly people. Patient Prefer Adherence. 2016;10:2117-2125. doi:10.2147/PPA.S118121
22. Manteuffel M, Williams S, Chen W, Verbrugge RR, Pittman DG, Steinkellner A. Influence of patient sex and gender on medication use, adherence, and prescribing alignment with guidelines. J Womens Health (Larchmt). Feb 2014;23(2):112-9. doi:10.1089/jwh.2012.3972
23. Nekui F, Galbraith AA, Briesacher BA, et al. Cost-related Medication Nonadherence and Its Risk Factors Among Medicare Beneficiaries. Med Care. Jan 2021;59(1):13-21. doi:10.1097/MLR.0000000000001458
24. Santoro N, Epperson CN, Mathews SB. Menopausal Symptoms and Their Management. Endocrinol Metab Clin North Am. 2015 Sep;44(3):497-515. doi: 10.1016/j.ecl.2015.05.001.